Linked Life Data

8075595

Source:http://linkedlifedata.com/resource/pubmed/id/8075595

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1994-10-6
pubmed:abstractText
An expression vector encoding the human recombinant fusion protein interleukin 6/interleukin 2 (IL-6/IL-2) was constructed. When a flexible linker had been synthesized and ligated with the IL-2 gene fragment by polymerase chain reaction (PCR) amplification, the IL-6 gene fragment was unidirectionally inserted into the upstream of the linker-IL-2 sequence. The molecule of the IL-6-linker-IL-2 fusion gene named E. coli DH5 alpha/pfIL-6/2 was cloned and identified by DNA sequencing. The expressed protein named as CH925 showed a strong band on SDS-PAGE and amounted to 32% of total cell protein, and its estimated molecular weight was about 37 kDa. The fusion protein purified by gel filtration and reversed-phase HPLC showed as almost homogeneous. CH925 possesses both IL-2 and IL-6 activities when assayed by CTLL2- and 7TD1-dependent cell lines, respectively. The specific activity of IL-2 was 2.1 x 10(6) U/mg while that of IL-6 was 2.3 x 10(8) U/mg. Our studies exhibited that CH925 exerted a significant augmentative effect on the growth of erythroid colony forming units (CFU-E), and synergized with erythropoietin (EPO) and/or IL-3 in a dose-dependent way. Our experimental results also showed CH925 at a low dose causing active lymphokine-activated killer (LAK) cell proliferation more vigorous than IL-2 and/or IL-6 (p < 0.001). CH925 is a novel fusion protein, being neither IL-6 nor IL-2, more potent than IL-2 and/or IL-6 and causing non-IL-2 and non-IL-6 functions of strong EPO-like and mild IL-3-like effects on erythroid progenitor cell growth. There is a potential for efficacious clinical application of CH925.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1066-5099
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
339-47
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:8075595-Base Sequence, pubmed-meshheading:8075595-Cell Division, pubmed-meshheading:8075595-Cell Line, pubmed-meshheading:8075595-Chromatography, Gel, pubmed-meshheading:8075595-Chromatography, High Pressure Liquid, pubmed-meshheading:8075595-Clone Cells, pubmed-meshheading:8075595-Cloning, Molecular, pubmed-meshheading:8075595-Colony-Forming Units Assay, pubmed-meshheading:8075595-DNA Primers, pubmed-meshheading:8075595-Drug Synergism, pubmed-meshheading:8075595-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:8075595-Erythroid Precursor Cells, pubmed-meshheading:8075595-Erythropoietin, pubmed-meshheading:8075595-Humans, pubmed-meshheading:8075595-Interleukin-2, pubmed-meshheading:8075595-Interleukin-3, pubmed-meshheading:8075595-Interleukin-6, pubmed-meshheading:8075595-Killer Cells, Lymphokine-Activated, pubmed-meshheading:8075595-Lymphocyte Activation, pubmed-meshheading:8075595-Molecular Sequence Data, pubmed-meshheading:8075595-Molecular Weight, pubmed-meshheading:8075595-Plasmids, pubmed-meshheading:8075595-Polymerase Chain Reaction, pubmed-meshheading:8075595-Protein Folding, pubmed-meshheading:8075595-Recombinant Fusion Proteins, pubmed-meshheading:8075595-Restriction Mapping
pubmed:year
1994
pubmed:articleTitle
Overexpression and characterization of recombinant human fusion protein IL-6/IL-2 (CH925).
pubmed:affiliation
Department of Experimental Hematology, Institute of Basic Medical Sciences, Beijing, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't